Scarica l'app Stockscreener
7.16
1.92%
-0.14
Precedente Chiudi:
$7.30
Aprire:
$7.38
Volume 24 ore:
790.21K
Relative Volume:
1.97
Capitalizzazione di mercato:
$479.64M
Reddito:
-
Utile/perdita netta:
$-122.44M
Rapporto P/E:
-3.1766
EPS:
-2.254
Flusso di cassa netto:
$-103.79M
1 W Prestazione:
-17.51%
1M Prestazione:
-26.79%
6M Prestazione:
+25.39%
1 anno Prestazione:
+33.83%
Intervallo 1D:
$6.94
$7.43
Intervallo di 1 settimana:
$6.60
$8.39
Portata 52W:
$2.65
$12.25
Engene Holdings Inc Stock (ENGN) Company Profile
Nome
Engene Holdings Inc
Settore
Industria
Telefono
(514) 332-4888
Indirizzo
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
7.16 | 479.64M | 0 | -122.44M | -103.79M | -2.254 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-11-11 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | Iniziato | Piper Sandler | Overweight |
| 2025-02-14 | Downgrade | UBS | Buy → Neutral |
| 2024-12-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-27 | Iniziato | Raymond James | Outperform |
| 2024-11-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-08-28 | Iniziato | Oppenheimer | Outperform |
| 2024-04-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-03-28 | Iniziato | UBS | Buy |
| 2024-03-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Engene Holdings Inc Borsa (ENGN) Ultime notizie
Oppenheimer Issues Pessimistic Forecast for enGene (NASDAQ:ENGN) Stock Price - Defense World
Merger Talk: Can enGene Holdings Inc Equity Warrant lead its sector in growth2026 Key Highlights & Reliable Price Action Trade Plans - baoquankhu1.vn
AI Stocks: Will enGene Holdings Inc stock benefit from M A2026 Short Interest & Entry and Exit Point Strategies - baoquankhu1.vn
enGene Holdings: Key Catalysts Incoming For 2026 (NASDAQ:ENGN) - Seeking Alpha
HC Wainwright Has Optimistic Outlook of enGene Q2 Earnings - MarketBeat
Citizens reiterates Engene Holdings stock rating on BLA timeline - Investing.com
FY2030 Earnings Forecast for enGene Issued By HC Wainwright - Defense World
enGene (NASDAQ:ENGN) Price Target Lowered to $30.00 at Oppenheimer - MarketBeat
Pullback Watch: How does enGene Holdings Inc compare to its peers2026 Highlights & Weekly High Return Opportunities - baoquankhu1.vn
ENGN: Detalimogene offers promising efficacy and convenience for NMIBC, with pivotal data updates ahead - TradingView
HC Wainwright Has Positive Outlook of enGene FY2030 Earnings - MarketBeat
Smart Money: Can SIFCO Industries Inc continue delivering strong returns2026 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
ENGN: Detalimogene's pivotal data and unique profile position it to transform NMIBC treatment - TradingView
enGene (NASDAQ:ENGN) Posts Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
ENGN: Detalimogene offers a unique, highly tolerable NMIBC therapy with pivotal data updates in 2024 - TradingView
Engene stock price target lowered to $27 by Guggenheim on estimates - Investing.com India
Raymond James Maintains Strong Buy on ENGN enGene Holdings Inc March 2026 - Meyka
enGene Holdings Inc. Q1 2026 Quarterly Report: Financial Statements, Management Discussion & Key Disclosures - Minichart
enGene Reports Q1 2026 Results, Advances Detalimogene for Bladder Cancer with Strong Cash Position and FDA Milestones 12 - Minichart
enGene Holdings Inc. Announces Sales Agreement with Leerink Partners LLC for At-the-Market Offering of Common Shares - Minichart
enGene (NASDAQ:ENGN) Shares Gap DownHere's Why - MarketBeat
Raymond James reiterates Engene Holdings stock Strong Buy rating By Investing.com - Investing.com South Africa
HC Wainwright Reiterates 'Buy' Rating for enGene Holdings (ENGN) - GuruFocus
enGene's (ENGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Raymond James reiterates Engene Holdings stock Strong Buy rating - Investing.com
enGene Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
ENGN: Holistic protocol changes and regulatory support position the program for a strong commercial launch - TradingView
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications - GlobeNewswire Inc.
enGene Strengthens Balance Sheet as Bladder Cancer Gene Therapy Nears Key 2026 Milestones - TipRanks
enGene Holdings Inc. (NASDAQ: ENGN) launches $100M ATM share program with Leerink - Stock Titan
Form 424B5 enGene Holdings Inc. - StreetInsider
Engene Holdings Enters Sales Agreement With Leerink Partners To Sell Common Shares - TradingView
enGene Holdings 10-Q: $0 Revenue, $0.44 Loss Per Share on $29.8M Net Loss - TradingView
enGene (NASDAQ: ENGN) details Q1 loss, LEGEND trial data and cash runway - Stock Titan
Published on: 2026-03-08 16:12:47 - baoquankhu1.vn
MACD Signal: Will enGene Holdings Inc. stock hit new highs in YEAR2025 Investor Takeaways & Precise Trade Entry Recommendations - baoquankhu1.vn
enGene Holdings Inc. $ENGN Stock Position Lowered by Blue Owl Capital Holdings LP - MarketBeat
Aug Ideas: Will enGene Holdings Inc stock benefit from M APortfolio Update Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Is enGene Holdings Inc Equity Warrant stock a value trapJuly 2025 Update & Consistent Return Investment Signals - baoquankhu1.vn
Growth Report: What are the analyst revisions for enGene Holdings IncIs FACT stock a good investment in YEARQuarterly Earnings Summary & Verified Short-Term Trading Plans - baoquankhu1.vn
New Highs: Is enGene Holdings Inc Equity Warrants ROE strong enough2025 Buyback Activity & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Growth Value: Will enGene Holdings Inc stock hit new highs in YEARWeekly Risk Summary & Daily Profit Focused Stock Screening - baoquankhu1.vn
ENGENE HOLDINGS INC C/WTS 31/10/2028 (TO PUR COM) CL A Stock Quote, Share Price, News and Analysis - Longbridge
Trade Report: What analysts say about enGene Holdings Inc Equity Warrant stockWeekly Investment Recap & Fast Gain Stock Tips - baoquankhu1.vn
[EFFECT] enGene Holdings Inc. SEC Filing - Stock Titan
enGene (ENGN) Expected to Announce Earnings on Monday - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 31.5% in February - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ENGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference - Yahoo Finance
ENGN: Detalimogene shows 62% six-month CR rate in NMIBC, with launch targeted for 2027 - TradingView
Engene Holdings Inc Azioni (ENGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):